Myomo Q1 product rev up 20% to $3.4M; record 438 pipeline patients added

MYOMO, INC.

2023-Q1 EPS reported -$0.11 revenue$3,446,708

Product revenue $3.4M, +20% YoY; total revenue $3.4M (-11% due to prior-year license fee).
Record 438 new pipeline patients from previous payers (+54% YoY); total pipeline 855 (+28%).
Cost per pipeline add $1,579 (down 53% YoY, 50% sequentially).
Net loss $2.6M ($0.11 per share) vs $2.8M ($0.43) in Q1 2022.
Guides 20-30% product revenue growth for 2023; cash $11M after April license fee.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MYOMO, INC. reported financial results for the three months ended March 31, 2023.

Period: the three months ended March 31, 2023
Result: reported results

Exact text from the filing

On May 10, 2023, Myomo, Inc, (the "Company") announced its financial results for the first quarter ended March 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

MYOMO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-020555

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.